Orphan Drug Model Should Include PGx Therapeutics, McClellan Says | GenomeWeb
WASHINGTON, DC – The existing regulatory model for orphan drug development should encourage sponsors to develop more personalized treatments in broader disease settings, former FDA Commissioner Mark McClellan said this week.
 
“What one might hope for … is that the approach that’s used for orphan drugs … could become much more of the norm for developing drugs for broader types of diseases,” McClellan said at a conference here hosted by the Personalized Medicine Coalition.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.